Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 2,663 Shares

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 2,663 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $31,689.70. Following the completion of the sale, the vice president directly owned 270,451 shares of the company’s stock, valued at $3,218,366.90. This represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Xencor Stock Up 6.0%

Shares of NASDAQ XNCR traded up $0.72 during mid-day trading on Wednesday, reaching $12.74. 704,223 shares of the company traded hands, compared to its average volume of 590,924. The company’s fifty day moving average is $12.96 and its two-hundred day moving average is $12.91. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The stock has a market cap of $934.35 million, a PE ratio of -10.27 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter in the prior year, the business earned ($0.62) earnings per share. The company’s revenue was down 46.6% on a year-over-year basis. On average, analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald lifted their price objective on Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Truist Financial assumed coverage on Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their target price on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Institutional Trading of Xencor

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in shares of Xencor during the 1st quarter worth approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Xencor by 9.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 3,692 shares during the period. Goldman Sachs Group Inc. lifted its position in Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares during the period. CWM LLC boosted its stake in Xencor by 159.1% during the second quarter. CWM LLC now owns 8,736 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 5,364 shares in the last quarter. Finally, AlphaQuest LLC increased its holdings in Xencor by 144.0% in the 2nd quarter. AlphaQuest LLC now owns 12,946 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 7,641 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.